Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.
Verschuere T, Van Woensel M, Fieuws S, Lefranc F, Mathieu V, Kiss R, Van Gool SW, De Vleeschouwer S. Verschuere T, et al. Among authors: van woensel m, van gool sw. J Neurooncol. 2013 Oct;115(1):9-17. doi: 10.1007/s11060-013-1201-8. Epub 2013 Jul 4. J Neurooncol. 2013. PMID: 23824536
Galectin-1 and immunotherapy for brain cancer.
Verschuere T, De Vleeschouwer S, Lefranc F, Kiss R, Van Gool SW. Verschuere T, et al. Among authors: van gool sw. Expert Rev Neurother. 2011 Apr;11(4):533-43. doi: 10.1586/ern.11.40. Expert Rev Neurother. 2011. PMID: 21469926 Review.
Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
Verschuere T, Toelen J, Maes W, Poirier F, Boon L, Tousseyn T, Mathivet T, Gerhardt H, Mathieu V, Kiss R, Lefranc F, Van Gool SW, De Vleeschouwer S. Verschuere T, et al. Among authors: van gool sw. Int J Cancer. 2014 Feb 15;134(4):873-84. doi: 10.1002/ijc.28426. Epub 2013 Sep 4. Int J Cancer. 2014. PMID: 23929302
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.
Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, Wilms G, Demaerel P, Goffin J, Van Calenbergh F, Menten J, Clement P, Debiec-Rychter M, De Vleeschouwer S. Ardon H, et al. Among authors: van gool sw, van calenbergh f. Cancer Immunol Immunother. 2012 Nov;61(11):2033-44. doi: 10.1007/s00262-012-1261-1. Epub 2012 Apr 22. Cancer Immunol Immunother. 2012. PMID: 22527250 Free PMC article. Clinical Trial.
Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration.
Van Woensel M, Wauthoz N, Rosière R, Mathieu V, Kiss R, Lefranc F, Steelant B, Dilissen E, Van Gool SW, Mathivet T, Gerhardt H, Amighi K, De Vleeschouwer S. Van Woensel M, et al. Among authors: van gool sw. J Control Release. 2016 Apr 10;227:71-81. doi: 10.1016/j.jconrel.2016.02.032. Epub 2016 Feb 21. J Control Release. 2016. PMID: 26902800
Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma.
Vandenberk L, Garg AD, Verschuere T, Koks C, Belmans J, Beullens M, Agostinis P, De Vleeschouwer S, Van Gool SW. Vandenberk L, et al. Among authors: van gool sw. Oncoimmunology. 2015 Sep 11;5(2):e1083669. doi: 10.1080/2162402X.2015.1083669. eCollection 2016 Feb. Oncoimmunology. 2015. PMID: 27057467 Free PMC article.
Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy.
Van Woensel M, Mathivet T, Wauthoz N, Rosière R, Garg AD, Agostinis P, Mathieu V, Kiss R, Lefranc F, Boon L, Belmans J, Van Gool SW, Gerhardt H, Amighi K, De Vleeschouwer S. Van Woensel M, et al. Among authors: van gool sw. Sci Rep. 2017 Apr 27;7(1):1217. doi: 10.1038/s41598-017-01279-1. Sci Rep. 2017. PMID: 28450700 Free PMC article.
150 results